v3.26.1
REVENUE AND SEGMENT INFORMATION (Tables)
 6 Months Ended
Jun. 30, 2026
REVENUE AND SEGMENT INFORMATION  
Schedule of analysis of revenue and Adjusted Operating Profit by geographical segment

​

​

​

​

​

Six months ended 30 June

​

2026

2025 1

Revenue by segment

£m

£m

North America

1,830

1,851

Europe

1,631

1,556

APAC

1,182

1,149

International

959

924

Group revenue

5,602

5,480

1

Following the change in operating model structure announced on 8 January 2026, 2025 figures have been restated 

​

​

​

​

Six months ended 30 June

​

2026

2025

Adjusted operating profit by segment

£m

£m

Group operating profit

1,172

1,203

Reconciling items between Group operating profit and Group adjusted operating profit2

192

40

Total

1,364

1,243

​

​

​

​

Six months ended 30 June

​

2026

2025 1

​

£m

£m

North America

425

389

Europe

522

441

APAC

292

274

International

193

172

Corporate and other unallocated

(68)

(33)

Total

1,364

1,243

1.Following the change in operating model structure announced on 8 January 2026, 2025 figures have been restated 
2.The reconciling items above include:
a)Net amortisation and impairment of intangible assets of £28m (2025: £26m).
b)Restructuring costs of £169m (2025: £26m).
Schedule of analysis of revenue by product

Analysis of revenue by product category is included below:

​

​

​

​

​

Six months ended 30 June

​

2026

2025

Revenue by product category

£m

£m

​

  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Oral Health

1,838

1,728

Vitamins, Minerals and Supplements

849

833

Pain Relief

1,323

1,286

Respiratory Health

850

893

Digestive Health

490

491

Therapeutic Skin Health and Other

252

249

Group revenue

5,602

5,480

​